Wells Fargo
CCCC icon

Wells Fargo’s C4 Therapeutics CCCC Stock Holding History

Wells Fargo’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Sell
452,701
-415,210
-48% -$1.42M ﹤0.01% 3561
2026
Q1 		$2.28M Buy
867,911
+58,651
+7% +$138K ﹤0.01% 3176
2025
Q4 		$1.55M Buy
809,260
+790,600
+4,237% +$1.87M ﹤0.01% 3643
2025
Q3 		$41.4K Buy
18,660
+17,131
+1,120% +$41.1K ﹤0.01% 5609
2025
Q2 		$2.19K Sell
1,529
-522,090
-100% -$759K ﹤0.01% 6206
2025
Q1 		$838K Buy
523,619
+487,313
+1,342% +$1.45M ﹤0.01% 3765
2024
Q4 		$131K Buy
36,306
+9,389
+35% +$46.7K ﹤0.01% 5046
2024
Q3 		$153K Buy
26,917
+1,156
+4% +$6.96K ﹤0.01% 4754
2024
Q2 		$119K Buy
25,761
+25,403
+7,096% +$152K ﹤0.01% 4827
2024
Q1 		$2.92K Sell
358
-944
-73% -$7.32K ﹤0.01% 5973
2023
Q4 		$7.36K Buy
1,302
+968
+290% +$2.21K ﹤0.01% 5902
2023
Q3 		$621 Buy
334
+23
+7% +$70 ﹤0.01% 6321
2023
Q2 		$855 Sell
311
-7,176
-96% -$23.1K ﹤0.01% 6356
2023
Q1 		$23.5K Buy
+7,487
New +$44.1K ﹤0.01% 5571
2022
Q4 		– Sell
-6,209
Closed -$54K – 7489
2022
Q3 		$54K Buy
6,209
+5,707
+1,137% +$59.2K ﹤0.01% 4917
2022
Q2 		$4K Sell
502
-18,282
-97% -$161K ﹤0.01% 6070
2022
Q1 		$456K Sell
18,784
-12,444
-40% -$302K ﹤0.01% 4472
2021
Q4 		$1M Buy
31,228
+2,852
+10% +$113K ﹤0.01% 4101
2021
Q3 		$1.27M Buy
28,376
+28,341
+80,974% +$1.21M ﹤0.01% 4041
2021
Q2 		$0 Sell
35
-5,244
-99% -$188K ﹤0.01% 6928
2021
Q1 		$195K Sell
5,279
-33,248
-86% -$1.32M ﹤0.01% 5160
2020
Q4 		$1.28M Buy
+38,527
New +$1.12M ﹤0.01% 3837

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo's CCCC Position: Q2 2026 in Review

Wells Fargo reduced its C4 Therapeutics (CCCC) stake by 48% in Q2 2026, selling an estimated $1.42M and leaving 452,701 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

Wells Fargo first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $2.28M in Q1 2026. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Wells Fargo held 452,701 shares of C4 Therapeutics worth $2.11M as of Q2 2026.
  • Wells Fargo sold 415,210 C4 Therapeutics shares in Q2 2026, an estimated $1.42M.
  • C4 Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3561 holding.
  • Wells Fargo first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Wells Fargo's C4 Therapeutics position peaked at $2.28M in Q1 2026.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.